Physician profile

Adil Salam

Pulmonary Disease · Trumbull, CT

NPI 1508850959

$3,010.33

in general payments reported to CMS, 2019-2025

25 companies · $22.34 in 2025

The $22.34 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$22.34

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Glaxosmithkline, LLC. $848.57 2019-2022
Astrazeneca Pharmaceuticals LP $368.31 2019-2020
Boehringer Ingelheim Pharmaceuticals, INC. $225.15 2019
Genentech USA, INC. $209.27 2019-2021
Insmed, INC. $196.41 2019-2020
Genzyme Corporation $160.77 2019
Sunovion Pharmaceuticals INC. $134.68 2019-2020
Novartis Pharmaceuticals Corporation $118.15 2019
Regeneron Healthcare Solutions, INC. $103.56 2019
Electromed, INC. $78.83 2019
Mylan Specialty L.P. $77.66 2019
Grifols USA, LLC $70.22 2019
Shire North American Group INC $69.39 2019
Lilly USA, LLC $59.40 2019-2020
Mallinckrodt Enterprises LLC $50.50 2019
Show all 25 companies
CompanyGeneral paymentsYearsTop products
Pfizer INC. $40.68 2019
Mallinckrodt Hospital Products INC. $38.37 2020
Jazz Pharmaceuticals INC. $29.03 2019
Philips North America LLC $28.66 2019
Pulmonx Corporation $22.34 2025 Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Chartis Catheter
Harmony Biosciences LLC $19.72 2020
United Therapeutics Corporation $18.08 2021
Janssen Pharmaceuticals, INC $15.51 2019
Seqirus USA INC $13.54 2019
Nabriva Therapeutics, Plc $13.53 2020

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Adil Salam

$3,010.33

in general payments reported 2019-2025

Years
2019-2025
Top company
Glaxosmithkline, LLC.
Context
The $22.34 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).

https://glasscript.com/doctor/295394/adil-salam

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.